AI Article Synopsis
- Research indicates that aspirin-sensitive asthmatics have an abnormal response to aspirin and cyclo-oxygenase inhibitors, affecting their platelets and leukocytes.
- Studies so far have not definitively identified the metabolic pathways that lead to bronchospasm in these patients.
- During bronchoconstriction after taking aspirin, there is an increase in serum levels of both tryptase, a mast cell activation marker, and eosinophil cationic protein (ECP), suggesting a link to inflammation; leukotriene antagonists may offer some protection for individuals experiencing bronchoconstriction.
Article Abstract
It had been postulated from earlier studies that platelets of aspirin-sensitive asthmatics reacted to aspirin and other cyclo-oxygenase inhibitors. Similarly, a generalized abnormality had been suggested in the regulation of arachidonic acid oxidative pathways in blood leukocytes of patients with aspirin-induced asthma. Studies of activation in vitro as well as in vivo assessment of polymorphonuclear leukocytes have not been conclusive of metabolic pathways inducing bronchospasm in aspirin-sensitive asthmatic patients. Serum levels of tryptase, a specific marker of mast cell activation, appear to increase during bronchoconstriction following ingestion of oral aspirin. Eosinophil cationic protein (ECP) levels in serum are concomitantly elevated. Leukotriene antagonists may partially protect individuals with allergen-provoked or aspirin-provoked bronchoconstriction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2500/108854194778702955 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!